

KING™

may very well be the master key to unlocking your body's full

POTENTIAL

Think about it this way ... If Testosterone is the pedal to the gas, then Myostatin is the brake. Myostatin decreases muscle growth and differentiation - regulate Myostatin downward, and you may very well be on the way to increasing your

MUSCLE GROWTH

Glyco-proteins are uniquely structured compounds, which are responsible for an array of activities, including hormone regulation. **KING™** is based on staggering research studies surrounding glyco-proteins and one single myostatin inhibitor in a previously undocumented dose. These studies allow us the ability to roll these very findings into one

"SUPER PILL" KING™†



Manufactured for and Distributed by:
CUTLER NUTRITION
Hollywood, FL 33312
To report an adverse event or for more information call: 1-541-306-5900 (in)
www.cutlernutrition.com

*THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.

† When combined with a proper exercise and nutrition regimen. Statements based on early-stage independent 3rd party in vivo and / or in vitro model scientific research data findings for individual ingredients.



KING™

mTOR ANABOLIC SIGNALING AGENT*†

CLINICALLY RESEARCHED INGREDIENTS

2.5X*
INCREASE IN
IGF-2 EXPRESSION†

4.5X*
INCREASE IN
MYOGENIC REGULATORY
FACTORS (MRFS)†

2X*
INCREASE IN
MUSCLE FIBERS†

MAY PROMOTE:

ENHANCED STRENGTH*†

LEAN MUSCLE MASS*†

ANABOLIC ACTIVITY*†

**60
CAPSULES**

DIETARY SUPPLEMENT

Supplement Facts

Serving Size 2 capsules
Servings Per Container 30

Amount Per Serving	% Daily Value
--------------------	---------------

Vitamin D3 (as cholecalciferol)	4,800 IU	1,200% DV
---------------------------------	----------	-----------

GLYCOPROTEIN MUSCLE GROWTH BLEND
(proprietary) 1g

Activator™ (as Phosphatidic Acid (Lysophosphatidic Acid, Phosphatidylserine, Phosphatidylcholine, Phosphatidylethanolamine, Phosphatidylinositol)) **

Niagen™ (as Nicotinamide riboside) **

** Daily Value (DV) not established.

Other Ingredients: Gelatin, microcrystalline cellulose, maltodextrin, silica, *Zingiber officinale* (root), *Capsicum annuum* (fruit), cellulose (as ethyl cellulose), *Oryza sativa* wax, magnesium stearate, stearic acid, FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No. 6 and titanium dioxide.

Niagen™ is a registered trademark of Chromadex, inc.

Please read entire label before use.

SUGGESTED USE:

Take two (2) capsules daily with food, or as recommended by a healthcare practitioner.

WARNINGS:


Not intended for use by persons under age 18. Do not exceed recommended dose. Do not take for more than eight (8) consecutive weeks. Get the consent of a licensed physician before using this product, especially if you are taking medication or have a medical condition. This product should not be taken by women. Do not take if you are pregnant, lactating or trying to become pregnant. Do not use if allergic or contraindicated to aspirin. Discontinue use two weeks prior to surgery or if stomach upset occurs. **KEEP THIS PRODUCT AND ALL SUPPLEMENTS OUT OF THE REACH OF CHILDREN.**



**X2 CAPSULES
DAILY**

Diagram of the role of select active ingredient in **KING™** on muscle growth and differentiation.

ACTIVE INGREDIENT IN KING™



During development, mesodermal stem cells become committed to the myogenic fate. Muscle precursors (myoblasts) remain in a proliferative state until they exit from the cell cycle and are instructed to differentiate. Differentiation is accompanied by cell fusion, where committed myoblasts become multinucleated myotubes. Noted, select active ingredient in **KING™** may help modulate cell proliferation and enhance myogenic cell differentiation by modulating the expression of key pro and antimyogenic factors, such as IGF-I, IGF-II, Follistatin, and Myostatin.

*EARLY STAGES OF SCIENTIFIC DATA BASED ON PRELIMINARY FINDINGS SUGGEST THE KEY ACTIVE INGREDIENT IN **KING™** MAY PLAY A SIGNIFICANT ROLE IN MUSCLE CELLS. *ENDOCRINOLOGY* 2011 AUG;152(8):2976-88.

